Richard Eisenstadt
Overview
Richard Eisenstadt received an average of $1M in total compensation, including $213K in salary, at PharmAthene between 2021 and 2022. Richard Eisenstadt also received $783K at AYTU BIOPHARMA in 2021 and an average of $788K at Neos Therapeutics from 2014 to 2019.
- 2022
- 2021
- 2019
- 2018
- 2017
- 2016
- 2015
- 2014
PharmAtheneChief Financial Officer
AYTU BIOPHARMAFormer Chief Financial Officer, Secretary and Treasurer since April
PharmAtheneChief Financial Officer
Neos TherapeuticsChief Financial Officer
Neos TherapeuticsChief Financial Officer
Neos TherapeuticsChief Financial Officer
Neos TherapeuticsChief Financial Officer
Neos TherapeuticsChief Financial Officer
Neos TherapeuticsChief Financial Officer
Source: SEC filings on August 16, 2023, April 7, 2022, August 16, 2022, April 21, 2020, April 24, 2019, April 30, 2018, April 28, 2017, and April 26, 2016.
Related executives
We found 39 more executives who work or worked at PharmAthene, AYTU BIOPHARMA, andNeos Therapeutics.
Vipin Garg
PharmAthene
Chief Executive Officer
Raymond Jordt
PharmAthene
Chief Business Officer
M Harris
PharmAthene
Chief Medical Officer
Joshua Disbrow
AYTU BIOPHARMA
Chief Executive Officer
Greg Pyszczymuka
AYTU BIOPHARMA
Chief Commercial Officer since January
Mark Oki
AYTU BIOPHARMA
Chief Financial Officer
M Roberts
PharmAthene
Chief Scientific Officer
William Brown
PharmAthene
Chief Financial Officer
News
PharmAthene CEO Vipin Garg's 2022 pay rises 9% to $2.9M
August 16, 2023
PharmAthene CEO Vipin Garg's 2021 pay jumps 83% to $2.6M
August 16, 2022
AYTU BIOPHARMA CEO Joshua Disbrow's 2021 pay jumps 291% to $6.2M
April 7, 2022
Neos Therapeutics CEO Gerald McLaughlin's 2019 pay falls 56% to $1.4M
April 21, 2020
Neos Therapeutics CEO Gerald McLaughlin receives $3.2M in 2018
April 24, 2019